Clinical trial
A Non-Randomized, Post Marketing Clinical Follow-Up (PMCF) Study of the DESyne X2 Novolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions
NCT04375085 is registered in ClinicalTrials.gov with Elixir Medical Corporation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non-Randomized, Post Marketing Clinical Follow-Up (PMCF) Study of the DESyne X2 Novolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions
- Lead sponsor
- Elixir Medical Corporation
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- September 1, 2020
- Completion date
- December 28, 2021
- Enrollment
- 49 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.